OR Regimen Refractory Marginal Zone Lymphoma Clinical Trial
Official title:
Prospective, Multicenter, Single-arm Clinical Study of Obrutinib Plus Rituximab for Second-line Treatment of Refractory Marginal Zone Lymphoma
The goal of this clinical trial is to test the overall response rate of obrutinib combined with rituximab (OR regimen) for second-line treatment of refractory marginal zone lymphoma.
n/a